Legal permission will no longer be required to end care for patients in a permanent vegetative state, a judge has ruled.
UK-based firm Remote Diagnostic Technologies (RDT) has introduced a new system, Tempus ALS, to enable monitoring and defibrillation to improve emergency responses.
A legal brawl between two of the world’s largest drug companies could shape the future of a nascent market of copycat drugs that are intended to bring down the cost of the most advanced and expensive medicines.
Symbiomix Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved its lead product Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.
(CNN)Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published Tuesday. Adding to the concern: It is likely that the speed of increasing resistance will outpace the slow drug development process.
ARUP Laboratories and metagenomics firm IDbyDNA have introduced a new next-generation sequencing (NGS) test, Explify Respiratory, for the diagnosis of respiratory diseases such as pneumonia.
Medtronic has secured the US Food and Drug Administration (FDA) approval for its next generation spinal cord stimulator branded as Intellis platform for the management of certain forms of chronic intractable pain.
A University of Otago, Wellington (UOW) team has been awarded an MBIE Endeavour grant to develop a non-invasive and cost-effective device to diagnose and treat stroke and other brain injuries.
Centinel Spine has agreed to acquire Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets for an undisclosed amount, according to an OrthoWorld report.
AbbVie (NYSE: ABBV), a global research and development-based biopharmaceutical company, today announced that the Phase 3 MURANO study of VENCLEXTA/VENCLYXTO (Venetoclax) Tablets in combination with Rituxan® (rituximab) met its primary endpoint.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.